SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice - 19/04/08
, Masahide Hamaguchi a, Takashi Nakamura b, Masayuki Okamoto b, Yukiharu Matsumoto c, Hirahito Endo d, Aihiro Yamamoto a, Hidetaka Ishino a, Makoto Wada a, Atsushi Omoto a, Yasunori Tsubouchi a, Masataka Kohno a, Toshikazu Yoshikawa a
Corresponding author. Tel.: +81 75 251 5505; fax: +81 75 252 3721.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis and excessive collagen deposition in the skin and various internal organs. In early stages of SSc, the dermis reveals infiltration of inflammatory cells associated with increased collagen synthesis. SKL-2841 was initially synthesized as a novel small molecule antagonist of MCP-1. In this study, we indicated that SKL-2841 also exerts anti-chemotactic activity for MIP-1 beta in mouse spleen cells. In the early stages of bleomycin-induced skin lesions, immunohistochemical analysis showed the expression of both MCP-1 and MIP-1 beta in dermal inflammatory cells. Moreover, intraperitoneal administration of SKL-2841 suppressed the infiltration of inflammatory mononuclear cells and polymorphonuclear cells in the acute phase and also significantly suppressed fibrillization in the chronic phase in bleomycin-induced scleroderma, compared with PBS treatment. These findings suggest that SKL-2841 has potential as a compound for the treatment of conditions associated with skin fibrosis such as SSc.
Le texte complet de cet article est disponible en PDF.Keywords : MCP-1, MIP-1 beta, Chemokine antagonist, Scleroderma
Abbreviations : SSc, MCP-1, MIP-1, CCR
Plan
Vol 61 - N° 4
P. 222-228 - mai 2007 Retour au numéro
Article précédent
- Nitric oxide generation is associated with an unbalance of protein tyrosine phosphatases during liver transplantation
- F. Carlucci, E. Marinello, F. Rosi, F. Floccari, G. Gerunda, D. Neri, A. Tabucchi
- Treatment of lycorine on SCID mice model with human APL cells
- J. Liu, Y. Li, L.J. Tang, G.P. Zhang, W.X. Hu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?